[ad_1]
Coronary tick trials from the University of Oxford and AstraZeneca in the UK have shown that the vaccine does not allow cavities to settle in 80 percent of people. While Pfizer and Modern have claimed 95 percent of the success of their ticker, the news is seen as disappointing and triumphant.
That said, the Oxford vaccine will be much cheaper than the other two vaccines, it will be relatively easier to store and spread to all corners of the world. That is why the vaccine could play an important role in treating the epidemic if approved by regulatory authorities. At the same time, there is information that if the vaccine becomes more accurate, its success rate will increase to 90 percent.
The UK government has already demanded 100 million doses of the Oxford vaccine, enough to protect 50 million people in the country. The government of Bangladesh has already signed an agreement with the Seram Institute of India and Beximco Pharmaceuticals Limited to purchase 30 million doses of the Oxford-AstraZeneca vaccine.
More than 20,000 volunteers from across the UK and Brazil participated in the Oxford Ticker Trial. Half of the volunteers are from the UK, the rest are from Brazil. Of these, two doses of the vaccine were administered to 30 patients with Kavid-19. And 101 people receive different vaccines. Researchers say the vaccine provides 80 percent protection. When the volunteers received two high doses, their coverage was 72 percent. And when a lower dose was given between the two doses, the protection was 90 percent. Why this difference is not yet clear.
Sarah Gilbert, Professor in the Department of Vacineology at the University of Oxford, said: We will be able to get rid of this horror using this vaccine.
Sarah Gilbert led the way in creating this vaccine. Sarah said: “We will continue to provide detailed information to vaccine regulators on vaccines on a regular basis. The whole world will benefit from this multinational effort.
Professor Andrew Pollard, director of the Oxford Vaccine Group and director of vaccine testing, said in a statement: “This shows that we have an effective vaccine that can save many lives. As we have seen, one dose of ours is approximately 90 percent. This was made possible by the hard work of volunteers and researchers from around the world to participate in the experiment. We thank them.
“Today will be an important milestone in our fight against the epidemic,” said Pascal Seriot, CEO of AstraZeneca Ticker. The efficacy and safety of this vaccine is confirmed by the fact that it is ultimately effective against Cavid-19. The vaccine will have an immediate effect in public health emergencies.
Vaccination in three countries in December: UK can approve Pfizer and Bioentech vaccines ahead of US. The National Health Service (NHS) has been asked to be ready for this before December 1.
According to the Telegraph, the ticker approval could be matched this week. UK regulators are ready to begin a formal evaluation of the vaccine.
And the US Food and Drug Administration said Friday it will hold a meeting on Dec. 10 to approve the vaccine. Monsef Slaui, director of the US Immunization Program, said that US citizens can be vaccinated as of December 11.
Germany can also start getting vaccinated against the crown next month. “There is reason to be optimistic that a vaccine will be approved in Europe this year,” said Jens Span, the country’s health minister. He called on the German government to establish a vaccination center in mid-December in preparation for vaccination.
And the Spanish prime minister, Pedro Sánchez, said yesterday that his country will carry out a massive immunization program starting in January. Within three months, a significant part of the country’s total population will be vaccinated. Sources: BBC, CNN, AFP.
[ad_2]
